Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

Authors	KREJCI Daniel OPALKA Petr KREJCI Jana ZEMANOVA Milada ZEMANOVA Petra KULTAN Juraj FISCHER Ondrej SKŘIČKOVÁ Jana BRATOVÁ Monika CERNOVSKA Marketa HRNCIARIK Michal ČOUPKOVÁ Helena HURDÁLKOVÁ Karolína BAŘINOVÁ Magda KOUBKOVA Leona DOLEZAL Daniel SAFANDA Martin PESEK Milos SVATON Martin
Year of publication	2021
Type	Article in Periodical
Magazine / Source	Anticancer Research
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://ar.iiarjournals.org/content/41/5/2597
Doi	http://dx.doi.org/10.21873/anticanres.15039
Keywords	NSCLC; chemotherapy; real-world data; bevacizumab; pemetrexed
Description	Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non small cell lung cancer (NSCLC) treatment. We conducted a real world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/ pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/ pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.